Ortet launches health AI lab with $500M commitment from Thoreau. Thoreau's commitment will support the development of the startup's compute and data infrastructure, health-focused AI models and research team. By Eve Bender, Healthcare Reporter | October 1, 2026 | 1:02 PM AI startup Ortet has launched with a $500 million commitment from health technology investment platform Thoreau to build AI models designed to connect clinical, biological, operational and financial health data. Ortet is led by cofounder and CEO Kyunghyun Cho, an AI researcher who previously established the frontier research team at Genentech. The company said it has already secured its initial GPU cluster and plans to work with healthcare customers as it develops and deploys its technology. WHAT IT DOES The New York-based company says it plans to develop a patient-centered foundation model that can be adapted across scientific research, clinical care, healthcare operations and financial administration. The $500 million commitment will support computer and data infrastructure, model training and deployment, and investments in research and talent. Ortet is building what it describes as a "full-stack AI platform" encompassing computing and data infrastructure, AI research, and the development and deployment of health-focused models. Rather than developing separate AI tools for individual tasks, Ortet says its approach is intended to connect information across areas including a patient's biology, treatment, outcomes and interactions with the healthcare system. "Patient health should improve with every interaction, but today its data, knowledge, and infrastructure remain too fragmented for that learning to happen at scale," said Cho in a statement. "Ortet is building at every layer of the AI stack so that advances in research can translate into systems that understand the complete context of a patient and support better decisions across the continuum of care." The company says the infrastructure will be designed to move research into production and allow its models to be continually updated as they are used across different healthcare settings. Cho said Ortet's aim is to turn research advances into systems that can develop a broader picture of an individual patient's health. Thoreau creates, invests in and acquires platforms serving providers, payers, employers, life sciences companies and government markets. Ortet is one of the firm's founding investments. MARKET SNAPSHOT Large investments in healthcare AI infrastructure and foundation models have accelerated this year. In January, NVIDIA and Eli Lilly and Company announced plans for an AI co-innovation lab in San Francisco, with the companies planning to invest up to $1 billion in infrastructure, workforce and computing power over five years. In March, Roche expanded its partnership with NVIDIA to create a hybrid-cloud AI factory. The infrastructure combines on-premises and cloud resources totaling more than 3,500 Blackwell GPUs to support drug discovery, clinical trial work and data analysis. In June, Abridge partnered with NVIDIA to develop an AI foundation model for clinical conversations, expanding the company's technology beyond clinical documentation. Eve Bender, healthcare reporter for MobiHealthNews Email: [email protected] MobiHealthNews is a HIMSS Media publication. Follow MobiHealthNews on LinkedIn: MobiHealthNews HIMSS is hosting the one-day AI Executive Leadership Summit in San Diego on Oct. 21, 2026, followed by its AI in Healthcare Forum Oct. 22-23. Register separately for the two events here and here. WATCH NOW: Closing gaps in ataxia care through telehealth

Can half a billion dollars fix healthcare AI? A massive new war chest is testing whether elite talent and unprecedented capital can finally build an AI that understands both biology and hospital billing. Yusuf Yeşil, MD, MIS A massive new war chest is testing whether elite talent and unprecedented capital can finally build an AI that understands both biology and hospital billing. Ortet is launching with a staggering $500 million funding commitment. Led by former Genentech AI scientists and backed by investment firm Thoreau, the startup wants to build a patient-centered foundation model. This is not just another niche software play. Ortet aims to connect biological, clinical, and financial data into a single system. The consolidation of capital. In healthcare AI, the middle class is disappearing. Yesil Science is seeing a highly concentrated trend where massive capital flows into a select few frontier labs. Ortet joins heavily funded players like Isomorphic Labs and Xaira Therapeutics. Investors are no longer interested in funding dozens of small, point-solution software tools. Instead, they are placing massive bets on a few entities attempting to build all-encompassing models. The integration trap. But can one model really bridge the gap between molecular biology and administrative billing? These fields operate on entirely different logic. Biology requires molecular precision. Billing requires navigating Byzantine regulatory codes. Merging them sounds logical on paper. In practice, training a single foundation model on such disparate datasets risks creating a system that is mediocre at everything and master of nothing. Ortet has the pedigree and the cash, but the operational hurdles of data integration are monumental. The industry is watching to see if $500 million is enough to bridge this divide. This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Yusuf Yeşil, MD, MIS. Clinical Biochemist & Health AI Founder & Medical Doctor at Yesil Science. Clinical Biochemistry Specialist (EuSpLM) and Health AI researcher focused on clinical decision support, diagnostic AI, and biomedical machine learning.